Management attributed overperformance in 2025 to strong execution across all segments and a successful first year of the 2025-2027 long-range plan. 2026 guidance assumes total company pricing will ...
Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results